Show simple item record

dc.contributor.authorHoneychurch, Jamie
dc.contributor.authorMelis, Monique H M
dc.contributor.authorDovedi, Simon J
dc.contributor.authorMu, L
dc.contributor.authorIllidge, Timothy M
dc.date.accessioned2013-10-30T09:58:26Z
dc.date.available2013-10-30T09:58:26Z
dc.date.issued2013-09
dc.identifier.citationImmunogenic potential of irradiated lymphoma cells is enhanced by adjuvant immunotherapy and modulation of local macrophage populations. 2013, 54 (9):2008-15 Leuk Lymphomaen
dc.identifier.issn1029-2403
dc.identifier.pmid23339450
dc.identifier.doi10.3109/10428194.2013.769219
dc.identifier.urihttp://hdl.handle.net/10541/304715
dc.description.abstractThe aim of this study was to assess the immunogenic potential of irradiated lymphoma cells in vivo and determine whether immunogenicity can be enhanced by modulation of the host immune system. Syngeneic murine lymphoma models irradiated ex vivo were used as an orthotopic cellular vaccination prior to challenge with viable tumor cells. We demonstrate that irradiated lymphoma cells are poorly immunogenic and that protective anti-tumor CD8 T-cell responses require the addition of immunostimulatory monoclonal antibody as an immune adjuvant, and increased frequency of antigen exposure by multiple vaccinations. Furthermore, we show the potential importance of macrophages in regulating immunogenicity of irradiated lymphoma cells and demonstrate that depletion of macrophages using clodronate-encapsulated liposomes considerably enhances primary vaccination efficacy in the presence of adjuvant anti-CD40 antibody. Our results demonstrate that the immunogenic potential of poorly immunogenic lymphoma cells dying after radiation therapy can be improved by modulation of the host immune system.
dc.language.isoenen
dc.rightsArchived with thanks to Leukemia & lymphomaen
dc.titleImmunogenic potential of irradiated lymphoma cells is enhanced by adjuvant immunotherapy and modulation of local macrophage populations.en
dc.typeArticleen
dc.contributor.departmentTargeted Therapy Group, Institute of Cancer Sciences, University of Manchester, Manchester Academic Health Sciences Centre, Paterson Institute for Cancer Research, Manchester, UK.en
dc.identifier.journalLeukemia & Lymphomaen
html.description.abstractThe aim of this study was to assess the immunogenic potential of irradiated lymphoma cells in vivo and determine whether immunogenicity can be enhanced by modulation of the host immune system. Syngeneic murine lymphoma models irradiated ex vivo were used as an orthotopic cellular vaccination prior to challenge with viable tumor cells. We demonstrate that irradiated lymphoma cells are poorly immunogenic and that protective anti-tumor CD8 T-cell responses require the addition of immunostimulatory monoclonal antibody as an immune adjuvant, and increased frequency of antigen exposure by multiple vaccinations. Furthermore, we show the potential importance of macrophages in regulating immunogenicity of irradiated lymphoma cells and demonstrate that depletion of macrophages using clodronate-encapsulated liposomes considerably enhances primary vaccination efficacy in the presence of adjuvant anti-CD40 antibody. Our results demonstrate that the immunogenic potential of poorly immunogenic lymphoma cells dying after radiation therapy can be improved by modulation of the host immune system.


This item appears in the following Collection(s)

Show simple item record